Navigation Links
UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver

Two UC Davis MIND Institute researchers will lead a symposium on relationships between genetic, epigenetic and environmental influences on the development of autism in children during the American Association for the Advancement of Science (AAAS) Annual Meeting, Feb. 16 -18 in Vancouver, Canada.

The symposium, "Autism: Genetic, Epigenetic and Environmental Factors Influencing Neural Networks," will be held Feb. 18. The researchers, both affiliated with the UC Davis MIND Institute, are Isaac Pessah, director of the UC Davis Children's Center for Environmental Health and Disease Prevention and a professor in the UC Davis School of Veterinary Medicine, and Janine LaSalle, professor in the Department of Medical Microbiology and Immunology and in the Rowe Program in Human Genetics.

A news briefing on the symposium will be held at 9 a.m. on Feb. 19 in Room 221 on the second Level of the Vancouver Convention Center.

Autism is a heterogeneous set of developmental disorders with complex etiologies. The goal of the symposium is to present a multidisciplinary perspective on how genetic, epigenetic and environmental factors can interact to promote autism risk. Other presenters will include symposium co-organizer Cindy Lawler of the National Institute of Environmental Health Sciences, Scott Selleck of Pennsylvania State University and Pat Leavitt of the University of Southern California.

Pessah, the symposium organizer, will address how understanding how low-level chemical exposures influence molecular, cellular and behavioral outcomes relevant to the development of autism will enlighten geneticists, neuroscientists and immunologists about autism's complex etiologies, and possibly yield novel intervention strategies. The inherent imbalances in neuronal connectivity in children at risk for autism are likely to provide the biological substrate for enhanced susceptibility to environmental triggers that are known to target signaling systems. He also will discuss how recent results from studies conducted by investigators at the UC Davis Center for Children's Environmental Health highlight examples of gene/environment interactions relevant to autism risk.

LaSalle will discuss her recent research into a particular flame-retardant chemical persistent in the environment, and how genetically engineered autism mice exposed to the substance were less fertile and their offspring were smaller, less sociable and demonstrated marked deficits in learning and long-term memory, when compared with the offspring of normal unexposed mice.

The research is the first to link genetics and epigenetics with exposure to a flame retardant chemical. Other findings of the research are that female offspring of mice exposed to BDE-47 spent half as much time interacting with other mice in a 10-minute sociability test when compared with controls. The reduced sociability in BDE-47 exposed females corresponded to reduced DNA methylation in females, regardless of genotype. In addition, genetic and environmental interaction effects in this study were specifically observed in females.


Contact: Phyllis K. Brown
University of California - Davis Health System

Related medicine news :

1. UC Davis researchers refine nanoparticles for more accurate delivery of cancer drugs
2. Lower risk of death linked with access to key attributes of primary care, UC Davis study shows
3. $6.3 million center at UCSF and UC Davis seeks ways to diagnose and prevent osteoarthritis
4. UC Davis researchers develop computer model for testing heart-disease drugs
5. UC Davis pain research may pave the way to understanding and controlling chronic pain
6. UC Davis surgeons test innovative device in patient with swallowing disorder
7. Inhaled steroids increase diabetes risk, say Lady Davis Institute researchers
8. UC Davis scientists find link between arthritis pain reliever and cardiovascular events
9. UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans
10. New UC Davis study finds early Alzheimers identification method
11. DavisPTnetwork Recruits Bloggers to Report Key Session Learning Points Live from APTA 2010
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: